BioStem Technologies ((BSEM)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BioStem Technologies is conducting a clinical study titled A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC. The study aims to evaluate the effectiveness of the BR-AC treatment, a human placental allograft, in promoting healing of non-healing venous leg ulcers (VLUs) compared to standard care alone. The significance of this study lies in its potential to improve healing outcomes for patients with chronic VLUs.
The intervention being tested is BR-AC, an amnion chorion layer placental membrane, used alongside standard care. The purpose of BR-AC is to enhance wound healing by providing a biological scaffold that supports tissue regeneration.
The study employs a randomized, controlled design with a parallel intervention model. It features single masking, where an independent reviewer assesses wound closure to minimize bias. The primary goal is to determine the treatment’s effectiveness in healing VLUs.
The study began on February 14, 2025, with primary completion expected within 12 weeks of treatment initiation. The last update was submitted on July 1, 2025. These dates are crucial as they guide the study’s progress and provide timelines for potential results.
This update could positively impact BioStem Technologies’ stock performance by showcasing potential advancements in wound care treatment. Investors may view this as a promising development, especially if the study results demonstrate significant improvements over standard care. Competitors in the wound care industry may also be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.